SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?


To: Miljenko Zuanic who wrote (814)5/20/2003 11:27:17 PM
From: Spartex  Respond to of 3559
 
<Please, let as know when you have sold REGN>

Ok, it's a deal! I bought my last REGN back in '99 in the $7-8 price range (watching insider buying back then), and sold out mostly in the $30's during '00-01. Maybe I got lucky in selling rather than getting greedy. Or I'm learning from my mistakes along the way, rather than repeating them (not taking profits).

I would think REGN could initially be valued near the $9-12 range before I would even consider selling any. I'm holding all my shares for now. I normally buy shares at distressed enough levels that getting 50-80% gain is not unusual within 12 months time. Hell, REGN is already up 50% for me in 1 month's time. But of course, no ones perfect in picking the bottom, but I will tell you I'm getting better all the time.



To: Miljenko Zuanic who wrote (814)5/21/2003 4:16:12 AM
From: nigel bates  Read Replies (1) | Respond to of 3559
 
Novartis got lucky in their timing, too (though luck probably isn't the right word) -

Novartis will purchase $48 million of newly issued Regeneron common stock...The price per share will be determined based on the average closing price of the common stock for the 20 consecutive trading days ending May 9, 2003....

finance.yahoo.com

A significant dilution at the price.